As a first attempt to explore the potential application of dCyaA as a vaccine vector for immunotherapeutic purposes in human, Dadaglio and colleagues characterized recombinant dCyaAs harboring CD8+ epitopes derived from tumor-associated antigens (TAA) that are overexpressed in melanoma [104]. The gene discussed is CD8A; the disease is neoplasm.